Study: DermACELL® demonstrates superior clinical outcomes compared to AlloDerm® in breast reconstruction

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/4/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to Study: DermACELL® demonstrates superior clinical outcomes compared to AlloDerm® in breast reconstruction

Canaccord Genuity Cuts Price Target on Novadaq Technologies (NVDQ) Following 4Q Preannouncement

January 11, 2017 8:24 AM EST

Canaccord Genuity reiterated a Buy rating on Novadaq Technologies (NASDAQ: NVDQ), and cut the price target to $10.00 (from $15.00), following the company's preannounced 4Q results.

Analyst... More